AZmed has received two clearances from the U.S. Food and Drug Administration (FDA) for its AI software, AZchest.
The clearances include applications intended to assist radiologists in the interpretation and detection of chest x-rays for lung nodules and triage capabilities for pneumothorax and pleural effusion, according to the firm.
Research has found that AZchest has a sensitivity for detecting lung nodules of 88.5% and a specificity of 82.9%, AZmed said, and its sensitivity for pneumothorax and pleural effusion is 94% and 91.3%, respectively.